Post by Symeres

Biotech is operating under a new set of rules, and ignoring what’s changing now could directly impact how quickly programs advance and ultimately reach patients. 🤔 That’s happening against a changing landscape of tighter funding, higher expectations on early data, and increasing pressure to demonstrate value earlier in development. In a recent @Specialty Chemicals feature, Symeres colleagues @Philip Payne and Dr @Goran Verspui discuss how this is changing development strategies, and why integration across discovery, development, and manufacturing is now critical. Key themes from the discussion:
 • A need for earlier decision-making driven by investor expectations
 • The importance of connected drug substance and drug product workflows
 • How advanced chemistry and AI-enabled approaches are improving efficiency
 • Why integrated scientific collaboration helps reduce risk and delays
 • The growing role of mid-sized CDMOs in balancing flexibility and depth The direction of travel is clear: success will be defined by how well teams can connect science, data, and execution earlier in the process. 👉 Read the full discussion here: https://brnw.ch/21x3P2b